Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods issued on 15 July 2015

Overview

The Therapeutic Goods Act 1989 was enacted by the Parliament of Australia to regulate the manufacturing, supply, and quality of therapeutic goods in the country. This Act was introduced to address the need for a cohesive regulatory framework that ensures the safety, efficacy, and quality of therapeutic goods available to the public. The Act provides the Therapeutic Goods Administration (TGA) with the authority to license manufacturers and importers of therapeutic goods, ensuring that these products meet the necessary standards before being made available in the market. The policy objective of the Act is to protect public health by providing a robust regulatory system that minimises risks associated with the use of therapeutic goods while facilitating innovation and accessibility in the healthcare sector. This legislative gazette from the Commonwealth of Australia, published on 15 July 2015 by Dr Harry Rothenfluh, acting on behalf of the Secretary of the Department of Health, notifies the revocation of various licences to manufacture therapeutic goods. The revocations were carried out under Section 41(1)(d) of the Therapeutic Goods Act 1989, at the request of the respective manufacturers, for companies such as DHL Supply Chain (Australia) Pty Limited, South Eastern Sydney Local Health District, and others. This action is part of the ongoing regulatory oversight by the TGA to ensure compliance with the Act's requirements and to maintain the integrity of the therapeutic goods supply chain.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities and individuals involved in the manufacture, supply, importation, and exportation of therapeutic goods in Australia. This Act governs the licensing and regulation of therapeutic goods to ensure they meet safety, quality, and efficacy standards. The Act applies to a wide range of entities, including pharmaceutical companies, medical device manufacturers, and health service providers, as well as to individuals such as healthcare professionals and consumers. The jurisdictional reach of the Act is national, extending across the Commonwealth of Australia, and it applies to all states and territories. The Therapeutic Goods Administration (TGA) is responsible for enforcing the Act, and it has the authority to issue licenses, impose penalties, and revoke licenses when necessary. The Act includes provisions for exemptions and exclusions, such as for research purposes or for goods used in clinical trials, which are detailed in subordinate legislation and guidelines. The revocation of manufacturing licenses under Section 41 of the Act is a significant regulatory action, often taken at the request of the manufacturer, as evidenced by the revocation notices published for various entities.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) provides the legal framework for the regulation of therapeutic goods in Australia. Specifically, Section 41(1)(d) (1) allows the Secretary of the Department of Health to revoke a licence to manufacture therapeutic goods upon request by the manufacturer. The document published by Dr. Harry Rothenfluh, a delegate of the Secretary, details the revocation of several such licences held by various entities, including DHL Supply Chain (Australia) Pty Limited and the South Eastern Sydney Local Health District, among others. Entities that hold a licence to manufacture therapeutic goods are subject to certain obligations and requirements under the Act. These include maintaining high standards of manufacturing quality and adhering to good manufacturing practices. They must also ensure that their products comply with the standards set out in the Therapeutic Goods Regulations 1990 and any other applicable regulations. Additionally, these entities must report any incidents of adverse events related to their products to the Therapeutic Goods Administration (TGA). Failure to comply with the provisions of the Act can result in serious consequences. Section 41(1)(d) (2) stipulates that the revocation of a licence is one such consequence. Additionally, breaches of other provisions of the Act can result in civil or criminal penalties. For instance, under Section 33DA (3), an individual or entity found guilty of an offence related to the supply of therapeutic goods can be subject to fines up to $66,000 for a corporation and $13,200 for an individual, or imprisonment for up to two years, or both. For more serious offences, such as those under Section 33DC, the maximum penalty can be a fine of up to $660,000 for a corporation and $132,000 for an individual, or imprisonment for up to ten years, or both. The revocation of a licence is, therefore, a significant penalty intended to ensure compliance with the regulatory requirements set out in the Act.